Japan To Send Investigators To Europe On H1N1 Flu Vaccine Safety Mission
This article was originally published in PharmAsia News
Following a decision to send investigators to Canada after a flu vaccine recall, Japan's Ministry of Health, Labor and Welfare has decided to send investigators to Europe to gather information on concerns of flu vaccine safety. The ministry will gather information on Novartis's H1N1 flu vaccine. The team plans to go to Switzerland or Germany, the two countries that currently approved the use of the vaccine, and assess adverse effects information. Novartis and UK drug maker GlaxoSmithKline have signed agreements to export flu vaccines to Japan for 49.5 million people. (Click here for more - Japanese language
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.